BTIG Reiterates Buy Rating on Haemonetics Corporation (HAE)

Market Context

Haemonetics Corporation operates in the Healthcare sector. The stock currently trades at $77.69 with a market capitalization of $4.1B. The stock has gained 1.1% over the past 52 weeks.

Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Haemonetics Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Haemonetics Corporation

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 26, 2026	BTIG	Buy	N/A
Jun 17, 2026	BTIG	Buy	N/A
Jun 15, 2026	Mizuho	Outperform	N/A
May 28, 2026	Citigroup	Neutral	N/A
May 22, 2026	B of A Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View HAE Stock Page